Shukla Sath 4
4 · Spero Therapeutics, Inc. · Filed Feb 5, 2025
Insider Transaction Report
Form 4
Shukla Sath
CEO & President
Transactions
- Award
Common Stock
2025-02-03+751,407→ 1,892,216 total - Sale
Common Stock
2025-02-05$0.78/sh−6,139$4,788→ 1,886,077 total - Sale
Common Stock
2025-02-05$0.78/sh−42,786$33,373→ 1,843,291 total - Sale
Common Stock
2025-02-05$0.78/sh−106,408$82,998→ 1,736,883 total
Footnotes (4)
- [F1]Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 3, 2026, subject to the Reporting Person's continued service through the applicable vesting date.
- [F2]The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2022.
- [F3]The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2023.
- [F4]The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2024.